Gelesis takes a Pass on COO
Gelesis said today that it named David Pass to be its new COO.
Pass, a JNJ, BMS and Boehringer Ingelheim (BI) for Diabetes veteran, is tasked with commercial planning, business development and all commercialization efforts for the Gelesis100 anti-obesity pill. Gelesis100 is designed to induce a feeling of satiety and improve glycemic control, using a super-absorbent hydrogelthat expands in the stomach after being swallowed.